Influenza A (H5N1) pandemic prototype vaccine Fluval®

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The timely development of safe and effective vaccines is likely to be the single most important public-health tool for decreasing the morbidity, mortality and economic effects of the influenza pandemic. The objective of this article is to provide a detailed description of the chemistry and immunogenicity of one of the better studied inactivated whole-virion aluminum phosphate-adjuvanted vaccines, Fluval® (Omninvest, Hungary), while we discuss safety data of all clinical trials published on H5N1 vaccines to date. Fluval was chosen for detailed discussion owing to its immunogenicity after only one dose, the fact that it was one of the very first H5N1 vaccines that demonstrated the potential for dose sparing and, unlike all mainstream oil-in-water adjuvanted reverse genetics-derived H5N1 vaccines, it is whole virion based.

Original languageEnglish
Pages (from-to)619-624
Number of pages6
JournalExpert Review of Vaccines
Volume8
Issue number5
DOIs
Publication statusPublished - May 1 2009

Fingerprint

Pandemics
Human Influenza
Vaccines
Virion
Reverse Genetics
Hungary
Oils
Public Health
Economics
Clinical Trials
Morbidity
Safety
Mortality
Water

Keywords

  • H5N1
  • Influenza
  • Pandemic
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Influenza A (H5N1) pandemic prototype vaccine Fluval®. / Vajó, Z.

In: Expert Review of Vaccines, Vol. 8, No. 5, 01.05.2009, p. 619-624.

Research output: Contribution to journalArticle

@article{914a4b2c21a64a319ed2f5a4c0e3e126,
title = "Influenza A (H5N1) pandemic prototype vaccine Fluval{\circledR}",
abstract = "The timely development of safe and effective vaccines is likely to be the single most important public-health tool for decreasing the morbidity, mortality and economic effects of the influenza pandemic. The objective of this article is to provide a detailed description of the chemistry and immunogenicity of one of the better studied inactivated whole-virion aluminum phosphate-adjuvanted vaccines, Fluval{\circledR} (Omninvest, Hungary), while we discuss safety data of all clinical trials published on H5N1 vaccines to date. Fluval was chosen for detailed discussion owing to its immunogenicity after only one dose, the fact that it was one of the very first H5N1 vaccines that demonstrated the potential for dose sparing and, unlike all mainstream oil-in-water adjuvanted reverse genetics-derived H5N1 vaccines, it is whole virion based.",
keywords = "H5N1, Influenza, Pandemic, Vaccine",
author = "Z. Vaj{\'o}",
year = "2009",
month = "5",
day = "1",
doi = "10.1586/erv.09.25",
language = "English",
volume = "8",
pages = "619--624",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Influenza A (H5N1) pandemic prototype vaccine Fluval®

AU - Vajó, Z.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - The timely development of safe and effective vaccines is likely to be the single most important public-health tool for decreasing the morbidity, mortality and economic effects of the influenza pandemic. The objective of this article is to provide a detailed description of the chemistry and immunogenicity of one of the better studied inactivated whole-virion aluminum phosphate-adjuvanted vaccines, Fluval® (Omninvest, Hungary), while we discuss safety data of all clinical trials published on H5N1 vaccines to date. Fluval was chosen for detailed discussion owing to its immunogenicity after only one dose, the fact that it was one of the very first H5N1 vaccines that demonstrated the potential for dose sparing and, unlike all mainstream oil-in-water adjuvanted reverse genetics-derived H5N1 vaccines, it is whole virion based.

AB - The timely development of safe and effective vaccines is likely to be the single most important public-health tool for decreasing the morbidity, mortality and economic effects of the influenza pandemic. The objective of this article is to provide a detailed description of the chemistry and immunogenicity of one of the better studied inactivated whole-virion aluminum phosphate-adjuvanted vaccines, Fluval® (Omninvest, Hungary), while we discuss safety data of all clinical trials published on H5N1 vaccines to date. Fluval was chosen for detailed discussion owing to its immunogenicity after only one dose, the fact that it was one of the very first H5N1 vaccines that demonstrated the potential for dose sparing and, unlike all mainstream oil-in-water adjuvanted reverse genetics-derived H5N1 vaccines, it is whole virion based.

KW - H5N1

KW - Influenza

KW - Pandemic

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=65649135422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649135422&partnerID=8YFLogxK

U2 - 10.1586/erv.09.25

DO - 10.1586/erv.09.25

M3 - Article

C2 - 19397418

AN - SCOPUS:65649135422

VL - 8

SP - 619

EP - 624

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 5

ER -